(Q34743706)

English

Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

1 reference

Europe PubMed Central

Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

0 references

Brigitte Dréno

6

object named as

Brigitte Dréno

0 references

1

object named as

Axel Hauschild

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

author name string

Helen Gogas

2

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Ahmad Tarhini

3

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Mark R Middleton

4

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Alessandro Testori

5

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

John M Kirkwood

7

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

language of work or name

0 references

publication date

1 March 2008

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

112

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

982-994

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Neuropsychiatric toxicity associated with cytokine therapies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

21 January 2018

Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

21 January 2018

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Does Adjuvant Vaccine Therapy Really Have Activity in Malignant Melanoma?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-mediated fatigue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Rhabdomyolysis, when observed with high-dose interferon-alfa (HDI) therapy, does not always exclude resumption of HDI

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of granisetron on performance status during high-dose interferon therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Mood disorders associated with interferon treatment: theoretical and practical considerations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe action tremor related to interferon-alpha 2b therapy for malignant melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug-induced tremors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Neuropsychiatric adverse effects of interferon-alpha: recognition and management

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Mood and cognitive disorders in cancer patients receiving cytokine therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug-induced depression: a systematic review to inform clinical practice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Neuropsychiatric complications associated with interferon-alpha-2b treatment of malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Paroxetine for the prevention of depression induced by high-dose interferon alfa

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety of the Treatment of Interferon-Alpha-Induced Depression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiotoxicity of interferon. A review of 44 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug-induced heart failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Reversible cardiomyopathy caused by administration of interferon alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Thyroid hormone and the cardiovascular system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Endocrine and neurological adverse effects of the therapeutic interferons

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Diabetes mellitus during interferon therapy for chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-alpha induced Raynaud's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Vascular events associated with alpha interferon therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term interferon-alpha therapy induces autoantibodies against epidermis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Impaired platelet aggregation in melanoma patients treated with interferon-alpha-2b adjuvant therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug-induced hypertriglyceridemia with and without pancreatitis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Visual side effects of pegylated interferon during therapy for chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Retinopathy associated with high-dose interferon alfa-2b therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnostic and therapeutic procedures for management of melanoma during pregnancy: risks for the fetus?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metast

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23251

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.23251

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34743706&oldid=2146435316"